key: cord-0879261-d3owu2ob
authors: Talavera, Blanca; García-Azorín, David; Martínez-Pías, Enrique; Trigo, Javier; Hernández-Pérez, Isabel; Valle-Peñacoba, Gonzalo; Simón-Campo, Paula; de Lera, Mercedes; Chavarría-Miranda, Alba; López-Sanz, Cristina; Gutiérrez-Sánchez, María; Martínez-Velasco, Elena; Pedraza, María; Sierra, Álvaro; Gómez-Vicente, Beatriz; Guerrero, Ángel; Arenillas, Juan Francisco
title: Anosmia is associated with lower in-hospital mortality in COVID-19
date: 2020-10-01
journal: J Neurol Sci
DOI: 10.1016/j.jns.2020.117163
sha: 49a0083225452106ac463b522cf8c4f4bb4e1c37
doc_id: 879261
cord_uid: d3owu2ob

BACKGROUND: Anosmia is common in Coronavirus disease 2019, but its impact on prognosis is unknown. We analysed whether anosmia predicts in-hospital mortality; and if patients with anosmia have a different clinical presentation, inflammatory response, or disease severity. METHODS: Retrospective cohort study including all consecutive hospitalized patients with confirmed Covid-19 from March 8th to April 11th, 2020. We determined all-cause mortality and need of intensive care unit (ICU) admission. We registered the first and worst laboratory parameters. Statistical analysis was done by multivariate logistic and linear regression. RESULTS: We included 576 patients, 43.3% female, and aged 67.2 years in mean. Anosmia was present in 146 (25.3%) patients. Patients with anosmia were more frequently females, younger and less disabled and had less frequently hypertension, diabetes, smoking habit, cardiac and neurological comorbidities. Anosmia was independently associated with lower mortality (OR: 0.180, 95% CI: 0.069–0.472) and ICU admission (OR: 0.438, 95% CI: 0.229–0.838, p = 0.013). In the multivariate analysis, patients with anosmia had a higher frequency of cough (OR: 1.96, 95%CI: 1.18–3.28), headache (OR: 2.58, 95% CI: 1.66–4.03), and myalgia (OR: 1.74, 95% CI: 1.12–2.71). They had higher adjusted values of hemoglobin (+0.87, 95% CI: 0.40–1.34), lymphocytes (+849.24, 95% CI: 157.45–1541.04), glomerular filtration rate (+6.42, 95% CI: 2.14–10.71), and lower D-dimer (−4886.52, 95% CI: −8655.29-(−1117.75)), and C-reactive protein (−24.92, 95% CI: −47.35-(−2.48)). CONCLUSIONS: Hospitalized Covid-19 patients with anosmia had a lower adjusted mortality rate and less severe course of the disease. This could be related to a distinct clinical presentation and a different inflammatory response.

Anosmia is one of the most characteristic symptoms of Coronavirus disease 2019 [1] , however the pathophysiology of the loss of smell remains unclear [2] [3] [4] .

It seems to be one of the commonest symptoms, however the reported frequency varies from 5.1% to 98.3% depending on the study and the studied population [5] .

It is suggested that anosmia might be related to a milder course, implying a less symptomatic course and a lower probability of hospitalization [6] [7] . The affected population is usually younger and more frequently female, two variables that are also associated with better prognosis of Covid-19, and which could partially justify it [1, [8] [9] .

However, the role of anosmia on Covid-19 severity and mortality in hospitalized patients has not been elucidated yet. Therefore, our aim was to evaluate whether the presence of anosmia influences the prognosis of Covid-19 in hospitalized patients. As secondary objectives, we analysed whether patients with anosmia had a distinct clinical presentation and/or laboratory profile, and we aimed to assess the course of the disease in these patients.

This is an observational study with a retrospective cohort design, conducted according to the strengthening the reporting in observational studies in epidemiology (STROBE)

[10] statement. The study was approved by the institutional review board of the Valladolid Este health area (PI-20-1751). Due to the emergency situation and risk of contagion, written informed consent was not required. The study setting was Hospital Clínico Universitario de Valladolid, a public tertiary academic hospital with a reference population of 280,000 habitants. Data were collected, analysed and interpreted by all authors, who reviewed and approved the manuscript.

Only symptomatic patients with a confirmed diagnosis according to the WHO protocols [11] were included. The diagnostic tests were either real-time reverse-transcriptasepolymerase-chain-reaction (RT-PCR) assay (LightMix Modular SARS-CoV-2, E-gene and LightMix Modular SARS-CoV-2 RdRP, Roche Diagnostics S.L.) of oropharyngealnasopharyngeal swab, sputum sample or lower respiratory tract sample; or serological tests with anti-SARS-CoV-2 IgM+IgA antibodies (ELISA; Vircell, S.L. Granada, Spain).

The Covid-19 symptom checklist of the emergency department (ED) of our hospital includes anosmia as one of the typical symptoms. We defined anosmia as the partial or complete loss of the sense of smell [12] . We included both hyposmia and anosmia altogether. We collected data from the electronic medical records, including primary care, ED and hospitalization. According to the local protocol, every patient under Covid-19 suspicion was followed up daily or every other day in primary care since the first contact until the complete resolution of symptoms. In those cases, in which the presence of anosmia was not described, we contacted all the patients or relatives by phone afterwards, and enquired about it. Patients were treated according to the national Covid-19 management protocol standard of care (SOC) [13] . Recruitment was probabilistic, and all consecutive patients were included. Data was extracted according to a predefined protocol by thirteen neurologists that were involved in the treatment of Covid-19 patients. The study period encompassed from March 8 th to April 11 th , 2020.

The follow-up of the patients included a minimum of 20 days since the hospitalization in all cases. the degree of disability/dependence prior to admission was determined by using the modified Rankin scale (mRS) [14] .

Clinical presentation included whether there was a suspected source of contagion or not, the time between the first symptom and the emergency department (ED) visit, and the presence of symptoms as fever, cough, expectoration, dyspnea, asthenia, chest pain, headache, myalgia, cutaneous rash, nausea, odynophagia, rhinorrhea, arthralgia, diarrhea, or vomiting.

Complementary tests variables included the modality of Covid-19 diagnosis, either by RT-PCR or serological tests, and the results of chest imaging (X-ray or Computerized Tomography (CT)). We analysed the results of laboratory work-up, including Treatment variables included the need of oxygen therapy, and the administration of any drugs according to the local standard of care (SOC), including hydroxychloroquine 400 mg bid for 5 days, lopinavir/ritonavir 400/100 mg bid, remdesivir 200mg first day followed by 9 days with 100mg, a single dose of 400mg of tocilizumab, methylprednisolone 250 mg three consecutive days or interferon beta-1b [13] . We assessed the presence of complications, including the confirmed use of mechanical ventilation, invasive ventilation, Intensive Care Unit (ICU) admission, and mortality. We analysed the all-cause in-hospital mortality rate.

As secondary endpoints, we studied the relationship between presence of anosmia and the need for ICU admission, and analysed whether anosmia was associated with distinct clinical and laboratory profiles in hospitalized COVID-19 patients.

Continuous variables are described using the mean and standard deviation (SD), or median and interquartile range (IQR). Discrete variables are expressed as number of cases and percentage. Comparison between variables was performed using the twosided chi-square tests for discrete variables, or Fisher's exact tests for the contrast of hypothesis with categorical variables, adjusting p-value by Bonferroni method for multiple comparisons. We used Student t-test for hypothesis testing of quantitative variables with a normal distribution. Statistical significance was defined as a P value <0.05. For the primary endpoint and the secondary endpoints of severity of the disease, we conducted firstly a univariate regression analysis. To adjust for the possible confounders and effect modifiers, those variables that showed a p-value ≤0.2 were included in a multivariate regression analysis. To compare if the frequency of clinical symptoms and laboratory results were associated with anosmia, we did a multivariate analysis and adjusted all the variables that had a p-value ≤0.2 when comparing the frequency between patients with and without anosmia. Discrete variables were analysed by a subsequent multivariable regression analysis and continuous variables by using multivariate linear regression. We present the odds ratio (OR) and 95% confidence intervals (CI). We assessed multicollinearity by using Variance Inflation Factor, considering critical multicollinearity if the value was >5. We did not estimate sample size in advance. Missing data was managed by complete case analysis. Statistical analyses were carried out using SPSS v.26 (IBM Corp. Armonk, NY).

During the study period, 580 consecutive patients were admitted to our hospital with a positive test for SARS-CoV-2, being excluded four of them (three patients were diagnosed while asymptomatic and were previously hospitalized by another mayor cause and one did not have an accessible admission record). The sample included, thus, 576 patients, 250 (43.3%) female, with a mean age of 67.2 (SD ± 14.7) years, ranging from 23 to 98 years. Anosmia was present in 146 (25.3%) cases. Patients with anosmia were more frequently female, younger, less disabled at baseline, and had hypertension, diabetes, smoking habit, cardiac disease, and CND less frequently. Table 1 shows demographic variables, vascular risk factors frequency, and comorbidities in the whole sample and in both groups, depending on the presence of anosmia.

All patients were able to answer the question about their olfactory capacity, because there was no patient that had to be intubated directly on admission with no later record on that question. 

The mean time between symptom onset and ED visit was 7.34 (SD ± 6.16) days), being more prolonged in patients with anosmia, 8.64 (SD ± 5.46) days vs. 6.9 (SD ± 6.33) days (p=0.003). Anosmia was present since the first day of symptoms in 89 (60.9%) cases, since the second day in 105 (71.9%) and within the first five days in 123 (84.2%) cases. 

The figure 1 presents the differences in the frequency of symptoms between patients with anosmia and without it. The most frequent symptoms on presentation were fever, After adjusting for all the variables that were different between the two groups at the baseline; including time from clinical onset to ED, baseline performance, age, sex, hypertension, smoking habit, and CND; patients with anosmia had a higher adjusted value of lymphocytes, hemoglobin, and lower D-dimer upon admission. During hospitalization, patients with anosmia had a higher adjusted value of lymphocytes, hemoglobin, glomerular filtration rate and lower D-dimer, and C-reactive protein. Table   4 shows the full results of the lineal regression analysis for the laboratory parameters. days. However, these studies did not take into account other well-known risk factors from their study population that might cofound the outcomes and one only showed a significant result after 20 days of clinical onset. These 20 days are considered by many to be the limit from when the disease starts to have a lower risk of complications [16- J o u r n a l P r e -p r o o f 18]. Therefore, we present a study that evaluates whether hospitalized patients with anosmia have a better prognosis, in terms of mortality, and severity of the disease.

The prevalence of anosmia in our inpatient study is 25.3%, lower than the 52.7%

prevalence reported in a recent meta-analysis [5] . If anosmia is associated with a less severe course of the disease, then the prevalence of anosmia in hospitalized patients might be lower. Other studies done in-hospital population report a 34% frequency, similar to the rate observed in our study [19] .

nosmia itself usually appears at the beginning of the infection [1, 9, The symptom of a 20-21] with a mean of 4.4 days after the clinical onset and a mean duration of approximately nine days described in a French study [8] . Anosmia was present since the first day in 60.9% of the patients from our study. In some cases, it has been presented as the only symptom of the disease [20] [21] . This fact is relevant for public health reasons, as patients with anosmia might be unaware of the disease and contribute to the dissemination of the infection [22] [23] .

As in other series, in our study, patients with anosmia were younger, with a higher percentage of women, less disability at baseline, and with fewer comorbidities [1-5, 7,24] . These characteristics have been associated with a better prognosis independently in Covid-19 [7, [25] [26] [27] [28] [29] [30] [31] [32] . Therefore, we adjusted the analysis to the known covariates related to Covid-19 mortality, and we still observed a lower probability of inhospital death in patients with anosmia. However, although the main causes of this association remain unknown, this finding could be related to a different clinical presentation and/or a milder immune or inflammatory response.

In our study, the presence of anosmia was independently associated with a higher odds of having cough, myalgia and headache. The clinical presence of headache has also shown to be associated to a better prognosis in some studies. These clinical are typical symptoms in other viral features appear at early stages of the disease and infections. Despite the physiopathology of these symptoms remains unknown, the higher frequency of systemic symptoms be linked with an increased systemic might response or viral replication and consequently, a sign of an efficient innate immunity response and better prognosis [ . It is important to highlight that rhinorrhea, which 2, 31] is one of the typical causes that could alter the smell, was not significantly associated with anosmia in our study as, in other studies [1] . It has been described its association with rhinorrhea and dysgeusia in 85% of the times [8, 31] , myalgia [17] and headache J o u r n a l P r e -p r o o f [31] , though some experts argue that dysgeusia may be caused by a lack of smell rather than affecting taste [24] .

We also assessed if the inflammatory response of patients with anosmia was different to the rest of the sample. In the crude comparison, many variables showed statistical signification. However, both populations were not comparable in terms of age, sex distribution, disability at baseline, or time since the onset of symptoms to the ED presentation. For that reason, we conducted a multivariate regression analysis including all those possible confounders and effect modifiers. In our sample, patients with anosmia had higher adjusted levels of lymphocytes, hemoglobin and lower levels of D-dimer on admission; and in the worst observed laboratory results during the whole hospitalization, they had higher levels of lymphocytes, hemoglobin and GFR, and lower of D-dimer and CRP. The alteration from most of these parameters has been associated with a worse prognosis and as an indirect measure of systemic inflammatory response [8, [25] [26] [27] [28] [29] [30] 34] . In fact, some authors recommend monitoring these parameters in the management of Covid-19 patients [34] . Consequently, patients with anosmia seem more likely to have a better analytical profile, suggesting that the inflammatory or immune response might be different and probably more benign.

Similarly, patients with anosmia were less likely to be admitted to ICU, even though there was no significant difference in the received treatment between the two groups in our study [35] . This finding is in line with other authors results, that described a milder disease course in patients with anosmia [8, 34, 36] . We encourage other authors to analyze if the clinical presentation of Covid-19 out-patients with anosmia also differs from those without it.

This study has several limitations. Firstly, it is a study conducted in an inpatient population. Likewise, the sample was drawn from a single center in which, the protocols and management may differ from the rest. Consequently, it would be interesting to include other hospitals from different areas for further studies. Secondly, this is a retrospective study in which all the data have been carefully collected and analyzed, although some might be incomplete. Thirdly, despite the acute and spontaneous onset of anosmia within the context of the diagnosis of Covid-19, neuroimaging studies were not performed in all the patients with anosmia. Thus, other causes, although infrequent, produced by anosmia could not be excluded, nor could their possible relationship be explained [37] . Fourthly, we did not evaluate the severity of anosmia, nor its duration or characteristics that could play a role in the endpoints.

Fifth, it might exist some degree of reporting bias and the most severe patients may not be able to describe symptoms by themselves; however we collected information regarding the period since the onset of the symptoms to the ED visit from the primary care electronic records.

In our study, the presence of anosmia was an independent predictor of good outcome as reflected by a lower in-hospital mortality rate and less frequent ICU admission. This could be related to a different clinical presentation that may be associated with a more benign immune and inflammatory response to SARS-COV-2. 

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Neurological complications of coronavirus and COVID-19. Complicaciones neurológicas por coronavirus y COVID-19

Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia

The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis

Features of anosmia in COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies

World Health Organization. Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans

Loss of smell

Hospital management of COVID-19

Reliability of the Modified Rankin Scale

Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study

Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol

Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study

Covid-19 med nedsatt lukte-og smakssans som eneste symptom. Tidsskrift for Den norske legeforening

Presentation of new onset anosmia during the COVID-19 pandemic

Anosmia and the Need for COVID-19

Olfactory Dysfunction in COVID-19

Coronavirus infection of rat dorsal root ganglia: Ultrastructural characterization of viral replication, transfer, and the early response of satellite cells

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of Coronavirus Disease 2019 in China

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: A retrospective cohort study. The Journal of Headache and Pain Editorial Office

Neurological comorbidity is a predictor of death in Covid-19 disease: a cohort study on 576 patients

New loss of smell and taste: Uncommon symptoms in COVID-19 patients on

Laboratory abnormalities in patients with COVID-2019 infection

Smell loss is a prognostic factor for lower severity of coronavirus disease

Olfactory Bulb Magnetic Resonance Imaging in SARS-CoV-2-Induced Anosmia: The First Report

mRS: Modified Rankin Scale. †Student T-Test, ‡Two-sided Fisher's Exact test